Diabetes pill may shield transplant patients from dangerous rejection
NCT ID NCT05149365
Summary
This study tested if adding the diabetes drug sitagliptin to standard medications could better prevent a dangerous immune reaction called graft-versus-host disease (GVHD) after a stem cell transplant. It involved 190 adults with blood cancers who received transplants from partially matched donors. Half received the standard drug regimen, and the other half received sitagliptin pills for two weeks in addition to the standard drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE-GRAFT-VERSUS-HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.